Research
2000
201-500 Employees
Centre de Regulació Genòmica (CRG)The work of the Centre for Genomic Regulation (CRG) focuses on understanding the complexity of life, from the genome in the cell to the complete organism and its interaction with the environment. All this is carried out by a multidisciplinary team that connects biology with physics, mathematics, chemistry and medicine, with the support of cutting-edge scientific services, which contribute to building the medicine of the future.

The main objectives of the CRG are to: a) achieve scientific excellence; b) communicate and establish a two-way dialogue with society; c) provide advanced training for the next generation of scientists; and d) transform new knowledge into benefits and value for society and the economy.
Address
Doctor Aiguader, 88 Edifici PRBB, 08003 Barcelona, Spain

Institutional Contact for Facilities/Platforms

MM

CERCAGINYS Facilities

GINYS-CRG-007

Tissue engineering

The goal of the Tissue Engineering Platform is to provide the CRG, PRBB and external researchers with the latest technologies used in the fields of stem cell biology, stem cell differentiation, organoid formation and induced pluripotent stem cells (iPSC). The Unit is constantly implementing new technologies that are emerging in the previous areas. The tissue engineering platform works in collaboration with the CRG’s Biomolecular Protein and Screening Technologies Unit to offer the CRISPR / Cas9 genome editing technology service. Since 2020, the Tissue Engineering Unit also includes the Internal Histology Service (only for PRBB residents). The Internal Histology Service was created in 2007 to provide the CRG with the histopathological analysis needed to analyze tissues based on research conducted in in vivo models. Studies of tissue developmental biology, homeostasis, and pathology require an in-depth analysis of the morphological and molecular characteristics of tissues and the alterations produced by manipulation. A common tool for these studies is to generate animal models that can recapitulate a specific process or a specific disease. Subsequently, histological and immunohistological analyzes are required to identify and characterize changes in cytoarchitecture and tissue morphology. Immunohistochemistry is an essential tool for determining the location of proteins and RNA at the cellular and tissue level. In this sense, the main objective of the Internal Histology Service is to perform and optimize the processing and histological analysis of the tissue, based on experimental animal models and of human origin. The service also offers advice and training in common histological techniques, in close collaboration with the different groups of the CRG.

CERCA GINYS

Participated Spin-Offs

Barcelona, Spain

2018

Flomics Biotech

Barcelona, Spain

2017

MICROOMICS SYSTEMS SL

Barcelona, Spain

2020

OMNISCOPE ESPAÑA SL

Barcelona, Spain

2022

ORIKINE BIO SL

Sant Cugat del Vallès, Spain

2020

PULMOBIOTICS SL

Barcelona, Spain

2021

SEQERA LABS SL

GINJOL Technologies

2019-06-011 - AONs2CureCancer - Splicing-modifying antisense oligonucleotides to treat lung cancer

We are developing an innovative therapy based on the use of Antisense Oligonucleotides (AONs) that regulate alternative splicing (AS) of the gene NUMB. AS is the process that allows the synthesis of different protein variants from a single gene by differential selection of exonic sequences. In this process, particular exons of a gene may be included within or excluded from the final processed mRNA produced from that gene. We previously characterized the RNA binding protein RBM10 as a regulator of NUMB exon 9 AS and showed that mutations in RBM10 disrupt RBM10-mediated AS of NUMB exon 9. This leads to higher levels of NUMB exon 9 inclusion and higher cell proliferation lung adenocarcinoma (LUAD) colony formation assays and in mouse tumour xenografts. Indeed, RBM10 is among the most frequently mutated genes in LUAD and increased inclusion of NUMB exon 9 is observed in the vast majority of LUAD tumours. The degree of exon 9 inclusion correlates with worse disease prognosis. Using our proprietary AONs, we have demonstrated that our novel therapy corrects NUMB exon 9 pathological inclusión caused by RBM10 mutations in LUAD, significantly inhibiting cancer cell proliferation, reducing tumour growth in four different mouse models of LUAD, including two patient-derived xenograft models in which we observe in addition an increased survival. We are currently finalizing the optimization of the AONs and administration route. After that, we are planning to start preclinical regulatory studies with our optimized preclinical candidate.

CERCA GÍNJOL

Main Domain of Research

Research Domain

Trustees

Trustees

Universities

Associated Universities

Sustainable Development Goals (SDG)

Objectius de Desenvolupament Sostenible (ODS)

Sustainable Development Goals (SDG)

*
Sustainable Development Goals

English name. Acronym

Acronim

ACRONYM
CRG